Recent 8-K filings for FHTX

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027

  Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).

• April 21, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory

  FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.

• March 11, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 7.01item 9.01

  Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

  Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.

• February 23, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02item 8.01item 9.01

  Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher

  Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 8.01item 9.01

  Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028

  Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).

• November 5, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 5.02item 7.01item 9.01

  Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028

  CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.

• October 30, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B

  Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).

• August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 7.01item 9.01

  Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track

  Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.

• July 1, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 1.02item 9.01

  Foghorn Therapeutics signs new 9-year lease for 72,846 sq ft HQ in Watertown, MA, terminates Cambridge lease

  New lease at 99 Coolidge Avenue, Watertown for 72,846 sq ft; annual base rent starts at $87/sq ft with partial abatement in years 1-2.

• May 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs

  Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).

• April 28, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing

  FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.

• March 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones

  Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).

• January 13, 2025, 6:59 PM ET other material materiality 0.65 positive item 2.02item 7.01item 9.01

  Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders

  Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.

• December 16, 2024, 6:59 PM ET other material materiality 0.65 negative item 7.01item 8.01item 9.01

  Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration

  FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.

• November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909

  Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.

• October 10, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers

  First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.

• August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024

  Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.

• May 22, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Foghorn Therapeutics raises ~$110M via public offering of common stock and pre-funded warrants

  Sold 12,743,039 shares of common stock at $5.51/share and pre-funded warrants for 7,220,794 shares at $5.5099 each.

• April 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×2

  Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024

  Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.

• April 9, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024

  FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.

• March 7, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024

  Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.

• February 8, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

  Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

11 positive 2 negative 26 neutral

source · FHTX on sec.gov